Alzheimer's drug study yields positive results, say makers Eisai and Biogen

Summary

This article by Deena Beasley, Julie Steenhuysen and Rocky Swift, writing for Reuters, makes the following points:

• To date, every drug tried to combat Alzheimers has failed.
• The brain-wasting disease affects about 55 million people globally.
• The new drug, Lecanemab, slowed the progress of the disease by 27%.
• The downside is that the drug is very expensive.

References

References from the Web:

• SEP 2022 Alzheimer’s Progression Slowed by Drug in Major Trial—Bloomberg
• SEP 2022 Biogen Stock Jumps 35% After Promising Results For New Alzheimer’s Drug—Forbes  

Source Information:

• Article Source: Reuters
• Media Check: Reuters - Media Bias Fact Check (mediabiasfactcheck.com)
• RAAF RUNWAY: RATIONALE, GUIDELINES, LEARNING OUTCOMES, ETC | The Runway (airforce.gov.au)